Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer

Cancer Biology and Therapy

Volumn 10, Issue 5, 2010, Pages 495-504

  Cole, Claire ^a   Lau, Sin ^b   Backen, Alison ^a   Clamp, Andrew ^a   Rushton, Graham ^a   Dive, Caroline ^a   Hodgkinson, Cassandra ^a   McVey, Rhona ^c   Kitchener, Henry ^c   Jayson, Gordon C ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b BLACKPOOL VICTORIA HOSPITAL   (United Kingdom)

^c ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Cisplatin; Fibroblast growth factor; Fibroblast growth factor receptor; Ovarian cancer; shRNAi

Indexed keywords

CISPLATIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MESSENGER RNA; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER TISSUE; CELL COUNT; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; OVARY CANCER; PROTEIN EXPRESSION; RESTRICTION MAPPING; SENSITIVITY ANALYSIS; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 77957116888     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.5.12585     Document Type: Article

References (18)

1. McGuire WP, Markman M. Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer 2003; 89:3-8.
2. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001; 2:1-12.
3. Orr-Urtreger A, Bedford MT, Burakova T, Arman E, Zimmer Y, Yayon A, et al. Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2). Dev Biol 1993; 158:475-86. (Pubitemid 23243904)
4. Hruza C, Dobianer K, Beck A, Czerwenka K, Hanak H, Klein M, et al. HER-2 and INT-2 amplification estimated by quantitative PCR in paraffin-embedded ovarian cancer tissue samples. Eur J Cancer 1993; 29:1593-7.
5. Rosen A, Sevelda P, Klein M, Dobianer K, Hruza C, Czerwenka K, et al. First experience with FGF-3 (INT-2) amplification in women with epithelial ovarian cancer. Br J Cancer 1993; 67:1122-5.
6. Seki A, Yoshinouchi M, Seki N, Kodama J, Miyagi Y, Kudo T. Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer. Int J Oncol 2000; 17:103-6.
7. Steele IA, Edmondson RJ, Bulmer JN, Bolger BS, Leung HY, Davies BR. Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer. Oncogene 2001; 20:5878-87.
8. Steele IA, Edmondson RJ, Leung HY, Davies BR. Ligands to FGF receptor 2-IIIb induce proliferation, motility, protection from cell death and cytoskeletal rearrangements in epithelial ovarian cancer cell lines. Growth Factors 2006; 24:45-53.
9. Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996; 271:15292-7. (Pubitemid 26195013)
10. Crickard K, Gross JL, Crickard U, Yoonessi M, Lele S, Herblin WF, et al. Basic fibroblast growth factor and receptor expression in human ovarian cancer. Gynecol Oncol 1994; 55:277-84.
11. Birrer MJ, Johnson ME, Hao K, Wong KK, Park DC, Bell A, et al. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol 2007; 25:2281-7.
12. Sahadevan K, Darby S, Leung HY, Mathers ME, Robson CN, Gnanapragasam VJ. Selective overexpression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol 2007; 213:82-90. (Pubitemid 47354569)
13. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22:7265-79.
14. Pardo OE, Latigo J, Jeffery RE, Nye E, Poulsom R, Spencer-Dene B, et al. The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. Cancer Res 2009; 69:8645-51.
15. Cummings BS and Schnellmann RG. Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J Pharmacol Exp Ther 2002; 302:8-17.
16. Shaulian E, Resnitzky D, Shifman O, Blandino G, Amsterdam A, Yayon A, Oren M. Induction of Mdm2 and enhancement of cell survival by bFGF. Oncogene 1997; 15:2717-25.
17. Miyake H, Hara I, Gohji K, Yamanaka K, Arakawa S, Kamidono S. Enhancement of chemosensitivity in human bladder cancer cells by adenoviral-mediated p53 gene transfer. Anticancer Res 1998; 18:3087-92.
18. Tartaglia M, Fragale A, Battaglia PA. A competitive PRC-based method to measure human fibroblast growth factor receptor 1-4 (FGFR1-4) gene expression. DNA Cell Biol 2001; 20:367-79. (Pubitemid 32692440)